Silver Book Fact

Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.

Early Treatment Diabetic Retinopathy Study. http://www.nei.nih.gov/neitrials/static/study53.asp

Reference

Title
Early Treatment Diabetic Retinopathy Study
Authors
National Institutes of Health, National Eye Institute
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Eye Exams: Trends, 1996-2006 (in relation to screening for diabetic retinopathy)  
  • Omega-3 polyunsaturated fatty acids have been found to protect against the development and progression of deterioration of the retina (retinopathy).  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.  
  • Gene transfer process treatment for diabetic retinopathy
    A gene transfer process that produces a VEGF receptor prevents retinal vascular permeability (RVP) associated with diabetes that could have value in treating diabetic retinopathy.  
  • The prevalence of age-related macular degeneration (AMD) in the 40 and older population has decreased from an estimated 9.4% from 1988 to 1994, to 6.5% for 2005 to 2008.